Therefore, the expression of PD‐L1 in tumor tissues may not serve as an independent marker for eligibility for anti‐PD‐1/PD‐L1 treatment, but it may represent a marker of better therapeutic response. This evidence concerns the gene PDCD1 and neoplasm.